Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 10.07% is 37% above its 5-year average of 7.35%, near the high end of its 5-year range (0.00%–10.89%).
41.83% above its 12-month average of 7.10%.
Annual fiscal-year return on assets; no daily interpolation. Historical series through 2025-12-31.
RETURN ON ASSETS (ROA)
10.07%
RETURN ON ASSETS (ROA) AVG TTM
7.10%
RETURN ON ASSETS (ROA) AVG 3Y
8.43%
RETURN ON ASSETS (ROA) AVG 5Y
7.35%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+41.83%
CURRENT VS 3Y AVG
+19.42%
CURRENT VS 5Y AVG
+37.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+95.91%
vs the sector median at left
Solventum Corporation
Market Cap
$15.51B
Return on Assets (ROA)
10.07%
TTM Avg
7.10%
3Y Avg
8.43%
5Y Avg
7.35%
Market Cap
$16.27B
Return on Assets (ROA)
23.89%
TTM Avg
21.05%
3Y Avg
19.32%
5Y Avg
16.45%
Market Cap
$14.56B
Return on Assets (ROA)
34.50%
TTM Avg
22.59%
3Y Avg
17.42%
5Y Avg
13.40%
Market Cap
$13.61B
Return on Assets (ROA)
1.97%
TTM Avg
2.19%
3Y Avg
1.89%
5Y Avg
3.83%
Market Cap
$13.19B
Return on Assets (ROA)
-3.17%
TTM Avg
-0.94%
3Y Avg
2.58%
5Y Avg
3.75%
Market Cap
$18.02B
Return on Assets (ROA)
3.54%
TTM Avg
3.64%
3Y Avg
3.29%
5Y Avg
2.38%
Market Cap
$12.57B
Return on Assets (ROA)
8.13%
TTM Avg
5.32%
3Y Avg
4.08%
5Y Avg
2.47%
Market Cap
$12.54B
Return on Assets (ROA)
-5.37%
TTM Avg
-3.64%
3Y Avg
-1.62%
5Y Avg
0.47%
Market Cap
$18.90B
Return on Assets (ROA)
-1.17%
TTM Avg
-5.49%
3Y Avg
-1.68%
5Y Avg
-1.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $15.51B | 10.07% | 7.10% | 8.43% | 7.35% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.27B | 23.89% | 21.05% | 19.32% | 16.45% |
| Exelixis, Inc. (EXEL)vs › | $14.56B | 34.50% | 22.59% | 17.42% | 13.40% |
| Revvity, Inc. (RVTY)vs › | $13.61B | 1.97% | 2.19% | 1.89% | 3.83% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.19B | -3.17% | -0.94% | 2.58% | 3.75% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.02B | 3.54% | 3.64% | 3.29% | 2.38% |
| Penumbra, Inc. (PEN)vs › | $12.57B | 8.13% | 5.32% | 4.08% | 2.47% |
| Baxter International Inc. (BAX)vs › | $12.54B | -5.37% | -3.64% | -1.62% | 0.47% |
| Viatris Inc. (VTRS)vs › | $18.90B | -1.17% | -5.49% | -1.68% | -1.68% |
| Encompass Health Corporation (EHC)vs › | $12.08B | 8.33% | 7.48% | 6.38% | 5.99% |
ROA
10.1%
ROE
29.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 10.89% |
| 2024-12-31 | 3.31% |
| 2023-12-31 | 9.65% |
| 2022-12-31 | 9.88% |
| 2021-12-31 | 10.37% |
| 2020-12-31 | 0.00% |
